Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.56 |
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6226495 | 0.88 | CHRNA7 (0.51) | CHRNA7NTRK1CDK19MTORMEN1 | |
| SCHEMBL4359738 | 0.85 | KMT2A (0.58) | CHRNA7MEN1KMT2ATMPRSS4P2RX1 | |
| SCHEMBL4350084 | 0.84 | MTOR (0.56) | CHRNA7MTORMEN1KMT2ATRPV1 | |
| SCHEMBL4350377 | 0.83 | CA12 (0.66) | MTORMEN1KMT2ATRPV1HTT | |
| SCHEMBL4346945 | 0.82 | NTRK1 (0.74) | CHRNA7NTRK1CDK19MEN1KMT2A | |
| SCHEMBL4348431 | 0.80 | MTOR (0.68) | MTORTRPV1NAMPTERCC1ERCC4 | |
| SCHEMBL4355887 | 0.80 | MTOR (0.67) | MTORMEN1KMT2ATRPV1NAMPT | |
| SCHEMBL18341428 | 0.80 | TMPRSS4 (0.81) | MEN1KMT2ATMPRSS4P2RX1CNR1 | |
| SCHEMBL4348962 | 0.78 | MTOR (0.50) | CHRNA7MTORTRPV1HTTNAMPT | |
| SCHEMBL6229028 | 0.78 | MTOR (0.56) | CHRNA7MTORMEN1KMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| CN-100546977-C | Suppress the new compound and the application thereof of rotamase | JERINI AG (DE) | 2009-10-07 | — | — | CN | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | CHRNA7 416/4885NTRK1 2802/4885CDK19 1461/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | CHRNA7 700/4885NTRK1 3171/4885CDK19 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.